Drug news
Erwinase (EUSA) is FDA approved for acute lymphoblastic leukemia
The FDA on 18 November 2011 has approved Erwinase from EUSA Pharma as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.Erwinase is currently approved in a number of countries, including Canada, the UK and several European Union member states.Many children with ALL develop allergy to current asparaginase products, and Erwinase provides a key therapeutic alternative. EUSA Pharma are based at Oxford Science Park, UK.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins